1. Home
  2. Research
  3. Research Groups
  4. Molecular Pathology of Cancer Group

Molecular Pathology of Cancer Group

Search for publications

Only original articles, editorials, guidelines.

  • Alonso-Gordoa T, Goodman M, Vulsteke C, Roubaud G, Zhang J, Parikh M, Piulats JM, Azaro A, James GD, Cavazzina R, Gangl ET, Thompson J, Pouliot G, Kumar R, Sweeney C.

    A phase II study (AARDVARC) of AZD4635 in combination with durvalumab and cabazitaxel in patients with progressive, metastatic, castration-resistant prostate cancer.

    ESMO open . 9(6): 103446-103446.

    [doi:10.1016/j.esmoop.2024.103446]

  • Makker V, Perez-Fidalgo JA, Valabrega G, Hamilton E, Van Gorp T, Sehouli J, Reginácová K, Richardson DL, Perri T, Oza AM, Miller DS, Alía EMG, De Giorgi U, Henry S, Spitz DL, Wimberger P, Bednaríková M, Chon HS, Martínez-Garcia J, Pisano C, Berek JS, Romero I, Scambia G, Fariñas-Madrid L, Buscema J, Schochter F, Li K, Kalyanapu P, Walker CJ, Vergote I.

    Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study.

    GYNECOLOGIC ONCOLOGY . 185: 202-211.

    [doi:10.1016/j.ygyno.2024.05.016]

  • Agarwal N, Castellano D, Alonso-Gordoa T, Arranz Arija JA, Colomba E, Gravis G, Mourey L, Oudard S, Fléchon A, Gonzalez M, Maroto PM, Schweizer MT, Gallardo E, Johnston E, Balar A, Haddad N, Appiah AK, Nacerddine K, Piulats JM.

    A Signal-finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration-Resistant Prostate Cancer: Results from CYCLONE 1.

    CLINICAL CANCER RESEARCH . 30(11): 2377-2383.

    [doi:10.1158/1078-0432.CCR-23-3436]

  • Fernández-Miranda I, Pedrosa L, González-Rincón J, Espinet B, de la Cruz Vicente F, Climent F, Gómez S, Royuela A, Camacho FI, Martín-Acosta P, Yanguas-Casás N, Domínguez M, Méndez M, Colomo L, Salar A, Horcajo B, Navarro M, García-Cosío M, Piris-Villaespesa M, Llanos M, García JF, Sequero S, Mercadal S, García-Hernández S, Navarro B, Mollejo M, Provencio M, Sánchez-Beato M.

    Generation and External Validation of a Histologic Transformation Risk Model for Patients with Follicular Lymphoma.

    MODERN PATHOLOGY . 37(7): 100516-100516. Number of citations: 2

    [doi:10.1016/j.modpat.2024.100516]

  • Borque-Fernando Á, Zapatero A, Manneh R, Alonso-Gordoa T, Couñago F, Domínguez-Esteban M, López-Valcárcel M, Rodríguez-Antolín A, Sala-González N, Sanmamed N, Maroto P.

    Recommendations on the treatment of metastatic hormone-sensitive prostate cancer: Patient selection.

    Actas Urologicas Espanolas . 48(9): 623-631.

    [doi:10.1016/j.acuroe.2024.05.008]

  • Schettini F, Blondeaux E, Molinelli C, Bas R, Kim HJ, Di Meglio A, Bernstein Molho R, Linn SC, Pogoda K, Carrasco E, Punie K, Agostinetto E, Lopetegui-Lia N, Phillips KA, Toss A, Rousset-Jablonski C, Acheritogaray M, Ferrari A, Paluch-Shimon S, Fruscio R, Cui W, Wong SM, Vernieri C, Dieci MV, Matikas A, Rozenblit M, Villarreal-Garza C, De Marchis L, Puglisi F, Vasconcelos de Matos L, Mariño M, Teixeira L, Graffeo R, Rognone A, Chirco A, Antone N, Abdou Y, Marhold M, Božovic-Spasojevic I, Cortés Salgado A, Carmisciano L, Bruzzone M, Curigliano G, Prat A, Lambertini M.

    Characterization of HER2-low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study.

    CANCER . 130(16): 2746-2762.

    [doi:10.1002/cncr.35323]

  • González-Martínez S, Kajabova VH, Pérez-Mies B, Carretero-Barrio I, Caniego-Casas T, Sarrió D, Moreno-Bueno G, Gión M, Perez-García J, Cortés J, Smolkova B, Palacios J.

    CDH1 methylation analysis in invasive lobular breast carcinomas with and without gene mutation.

    VIRCHOWS ARCHIV . 485(2): 291-297.

    [doi:10.1007/s00428-024-03814-8]

  • Cristina-Marianini-Rios, Sanchez MEC, de Paredes AGG, Rodríguez M, Barreto E, López JV, Fuentes R, Beltrán MM, Sanjuanbenito A, Lobo E, Caminoa A, Ruz-Caracuel I, Durán SL, Olcina JRF, Blázquez J, Sequeros EV, Carrato A, Ávila JCM, Earl J.

    The best linear unbiased prediction (BLUP) method as a tool to estimate the lifetime risk of pancreatic ductal adenocarcinoma in high-risk individuals with no known pathogenic germline variants.

    FAMILIAL CANCER . 23(3): 233-246. Number of citations: 1

    [doi:10.1007/s10689-024-00397-w]

  • Earl J, Fuentes R, Sanchez MEC, de Paredes AGG, Muñoz M, Sanjuanbenito A, Lobo E, Caminoa A, Rodríguez M, Barreto E, López JV, Ruz-Caracuel I, Durán SL, Olcina JRF, Sánchez BL, Páez SC, Torres A, Blázquez J, Sequeros EV, Carrato A.

    The Spanish Familial Pancreatic Cancer Registry (PANGENFAM): a decade follow-up of individuals at high-risk for pancreatic cancer.

    FAMILIAL CANCER . 23(3): 383-392. Number of citations: 1

    [doi:10.1007/s10689-024-00388-x]

  • Martínez-Hernández R, Serrano-Somavilla A, Fernández-Contreras R, Sanchez-Guerrero C, Sánchez de la Blanca N, Sacristán-Gómez P, Sebastian-Valles F, Sampedro-Núñez M, Fraga J, Calatayud M, Vicente A, García-de-Casasola G, Sanz-García A, Araujo-Castro M, Ruz-Caracuel I, Puig-Domingo M, Marazuela M.

    Primary Cilia as a Tumor Marker in Pituitary Neuroendocrine Tumors.

    MODERN PATHOLOGY . 37(5): 100475-100475.

    [doi:10.1016/j.modpat.2024.100475]

  • Gebhart G, Keyaerts M, Guiot T, Flamen P, Ruiz-Borrego M, Stradella A, Bermejo B, Escriva-de-Romani S, Calvo Martínez L, Ribelles N, Fernandez-Abad M, Albacar C, Colleoni M, Garrigos L, Atienza de Frutos M, Dalenc F, Prat A, Marmé F, Schmid P, Kerrou K, Braga S, Gener P, Sampayo-Cordero M, Cortés J, Pérez-García JM, Llombart-Cussac A.

    Optimal [(18)F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial.

    JOURNAL OF NUCLEAR MEDICINE . 65(5): 708-713.

    [doi:10.2967/jnumed.123.266384]

  • López-Gil JC, García-Silva S, Ruiz-Cañas L, Navarro D, Palencia-Campos A, Giráldez-Trujillo A, Earl J, Dorado J, Gómez-López G, Monfort-Vengut A, Alcalá S, Gaida MM, García-Mulero S, Cabezas-Sáinz P, Batres-Ramos S, Barreto E, Sánchez-Tomero P, Vallespinós M, Ambler L, Lin ML, Aicher A, García García de Paredes A, de la Pinta C, Sanjuanbenito A, Ruz-Caracuel I, Rodríguez-Garrote M, Guerra C, Carrato A, de Cárcer G, Sánchez L, Nombela-Arrieta C, Espinet E, Sanchez-Arevalo Lobo VJ, Heeschen C, Sainz B Jr.

    The Peptidoglycan Recognition Protein 1 confers immune evasive properties on pancreatic cancer stem cells.

    Gut . 73(9): 1489-1508.

    [doi:10.1136/gutjnl-2023-330995]

  • Pothuri B, Han S, Chase DM, Heitz F, Burger RA, Gaba L, Van Le L, Guerra E, Bender D, Korach J, Cloven N, Churruca C, Follana P, DiSilvestro P, Baurain JF, Jardon K, Pisano C, Peen U, Mäenpää J, Gupta D, Bacqué E, Li Y, Compton N, Antonova J, Monk BJ, González-Martín A.

    Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial.

    GYNECOLOGIC ONCOLOGY . 184: 168-177. Number of citations: 1

    [doi:10.1016/j.ygyno.2024.01.021]

  • Pérez-García JM, Cortés J, Ruiz-Borrego M, Colleoni M, Stradella A, Bermejo B, Dalenc F, Escrivá-de-Romaní S, Calvo Martínez L, Ribelles N, Marmé F, Cortés A, Albacar C, Gebhart G, Prat A, Kerrou K, Schmid P, Braga S, Di Cosimo S, Gion M, Antonarelli G, Popa C, Szostak E, Alcalá-López D, Gener P, Rodríguez-Morató J, Mina L, Sampayo-Cordero M, Llombart-Cussac A.

    3-year invasive disease-free survival with chemotherapy de-escalation using an (18)F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial.

    Lancet (London, England) . 403(10437): 1649-1659. Number of citations: 4

    [doi:10.1016/S0140-6736(24)00054-0]

  • Peters S, Angevin E, Alonso-Gordoa T, Rohrberg K, Melero I, Mellado B, Perez-Gracia JL, Tabernero J, Adessi C, Boetsch C, Watson C, Dal Porto J, Dejardin D, DelNagro C, Nicolini V, Evers S, Klein C, Leutgeb B, Pisa P, Rossmann E, Saro J, Umana P, Charo J, Teichgräber V, Steeghs N.

    Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors.

    CLINICAL CANCER RESEARCH . 30(8): 1630-1641.

    [doi:10.1158/1078-0432.CCR-23-2658]

  • Motzer RJ, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Alekseev B, Rha SY, Merchan J, Goh JC, Lalani AA, De Giorgi U, Melichar B, Hong SH, Gurney H, Méndez-Vidal MJ, Kopyltsov E, Tjulandin S, Gordoa TA, Kozlov V, Alyasova A, Winquist E, Maroto P, Kim M, Peer A, Procopio G, Takagi T, Wong S, Bedke J, Schmidinger M, Rodriguez-Lopez K, Burgents J, He C, Okpara CE, McKenzie J, Choueiri TK.

    Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study.

    JOURNAL OF CLINICAL ONCOLOGY . 42(11): 1222-1228. Number of citations: 5

    [doi:10.1200/JCO.23.01569]

  • Conde E, Hernandez S, Rodriguez Carrillo JL, Martinez R, Alonso M, Curto D, Jimenez B, Caminoa A, Benito A, Garrido P, Clave S, Arriola E, Esteban-Rodriguez I, De Castro J, Sansano I, Felip E, Rojo F, Dómine M, Abdulkader I, Garcia-Gonzalez J, Teixido C, Reguart N, Compañ D, Insa A, Mancheño N, Palanca S, Juan-Vidal O, Baixeras N, Nadal E, Cebollero M, Calles A, Martin P, Salas C, Provencio M, Aranda I, Massuti B, Lopez-Vilaro L, Majem M, Paz-Ares L, Lopez-Rios F.

    RET Fusion Testing in Patients With NSCLC: The RETING Study.

    Jto Clinical And Research Reports . 5(4): 100653-100653.

    [doi:10.1016/j.jtocrr.2024.100653]

  • Freyer G, Martinez-Jañez N, Kukielka-Budny B, Ulanska M, Bourgeois H, Muñoz M, Morales S, Calero JB, Cortesi L, Pintér T, Palácová M, Cherciu N, Petru E, Ettl J, de Almeida C, Villanova G, Raymond R, Minh CTT, Rodrigues A, Cazzaniga ME.

    Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer: The randomized Tempo Breast study.

    Breast . 74: 103681-103681.

    [doi:10.1016/j.breast.2024.103681]